Alvotech (ALVO)

$4.64 +0.04 (0.87%)
Market Cap 1.39B
Revenue (ttm) 489.68M
Net Income (ttm) -231.86M
EPS (ttm) N/A
PE Ratio 21.04
Forward PE 79.17
Profit Margin -47.35%
Debt to Equity Ratio -6.36
Volume 1,233,500
Avg Vol 559,064
Day's Range N/A - N/A
Shares Out 301.48M
Stochastic %K 27%
Beta 0.13
Analysts Sell
Price Target $10.50

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosim...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Address:
9, Rue de Bitbourg, Luxembourg, Luxembourg
Spytime
Spytime Dec. 3 at 2:39 PM
$ALVO Adding more short position today. Technical drop deep. Do it bear.
1 · Reply
Spytime
Spytime Dec. 3 at 12:37 PM
$ALVO another great day is coming. Keep selling all day long.
0 · Reply
Spytime
Spytime Dec. 2 at 9:10 PM
$ALVO Let's go Bear. Keep shorting this daily. Price is not low yet.
1 · Reply
mikesterz7
mikesterz7 Nov. 24 at 12:20 PM
$ALVO 🚨 AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said.
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 24 at 11:56 AM
Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug $ALVO $IBBQ $PRFZ https://stocktwits.com/news/equity/markets/alvotech-drug-approved-in-europe-as-biosimilar-for-bone-disease-drugs/cL5bIelREQc
0 · Reply
nopeZ3
nopeZ3 Nov. 24 at 11:10 AM
$ALVO In at 5.14
0 · Reply
G101SPM
G101SPM Nov. 24 at 11:00 AM
$ALVO $5.14 ask. BUY/NEW LONG POSITION carries SPM 86.45 tag to $12.50 in long term (18 months).
0 · Reply
mru01
mru01 Nov. 24 at 10:57 AM
$ALVO great news!
0 · Reply
islandpunk
islandpunk Nov. 24 at 10:57 AM
$ALVO trending #5. let's go.
0 · Reply
islandpunk
islandpunk Nov. 24 at 10:34 AM
$ALVO Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area https://www.stocktitan.net/news/ALVO/alvotech-announces-approval-of-avt03-a-biosimilar-to-prolia-and-ksdimzmoqfjy.html
0 · Reply
Latest News on ALVO
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

Dec 2, 2025, 8:10 PM EST - 1 day ago

Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Nov 24, 2025, 5:30 AM EST - 10 days ago

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Nov 20, 2025, 4:00 AM EST - 14 days ago

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Alvotech (ALVO) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 10:51 AM EST - 21 days ago

Alvotech (ALVO) Q3 2025 Earnings Call Transcript

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Nov 12, 2025, 4:40 PM EST - 21 days ago

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 10, 2025, 5:28 PM EST - 23 days ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 6:28 PM EST - 27 days ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Nov 6, 2025, 9:07 AM EST - 4 weeks ago

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Nov 4, 2025, 4:01 PM EST - 4 weeks ago

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Alvotech Shares Plunge 33% After FDA Flags Issues

Nov 3, 2025, 1:17 PM EST - 4 weeks ago

Alvotech Shares Plunge 33% After FDA Flags Issues

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Nov 2, 2025, 5:12 PM EST - 4 weeks ago

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Oct 22, 2025, 5:00 AM EDT - 6 weeks ago

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Alvotech: Promising Vertically Integrated Biosimilar Platform

Oct 15, 2025, 4:18 AM EDT - 7 weeks ago

Alvotech: Promising Vertically Integrated Biosimilar Platform

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 2 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV AMGN ARKG AZN BIIB BMY GILD

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Oct 6, 2025, 4:40 AM EDT - 2 months ago

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

Sep 22, 2025, 6:15 AM EDT - 2 months ago

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Sep 22, 2025, 4:30 AM EDT - 2 months ago

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Sep 19, 2025, 7:45 AM EDT - 2 months ago

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 1:28 PM EDT - 3 months ago

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Sep 4, 2025, 9:15 AM EDT - 3 months ago

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Aug 21, 2025, 4:30 AM EDT - 3 months ago

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Aug 20, 2025, 6:05 AM EDT - 3 months ago

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 11:38 AM EDT - 4 months ago

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 4 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 4 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Aug 6, 2025, 8:00 AM EDT - 4 months ago

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Jul 10, 2025, 4:40 AM EDT - 5 months ago

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Jul 9, 2025, 4:30 AM EDT - 5 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Jul 9, 2025, 4:30 AM EDT - 5 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Jul 3, 2025, 7:02 PM EDT - 5 months ago

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Granting of Stock Options and Vesting of Restricted Share Units

Jul 1, 2025, 7:54 PM EDT - 5 months ago

Granting of Stock Options and Vesting of Restricted Share Units

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

Jul 1, 2025, 4:00 AM EDT - 5 months ago

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

Jun 26, 2025, 4:15 AM EDT - 5 months ago

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

Main Results of 2025 Annual and Extraordinary General Meeting

Jun 25, 2025, 4:45 PM EDT - 5 months ago

Main Results of 2025 Annual and Extraordinary General Meeting

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 25, 2025, 4:00 AM EDT - 5 months ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 25, 2025, 4:00 AM EDT - 5 months ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 23, 2025, 4:00 AM EDT - 5 months ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 23, 2025, 4:00 AM EDT - 5 months ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Jun 11, 2025, 4:20 PM EDT - 6 months ago

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Jun 11, 2025, 4:18 PM EDT - 6 months ago

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Jun 6, 2025, 8:30 AM EDT - 6 months ago

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami

Jun 6, 2025, 8:30 AM EDT - 6 months ago

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

Jun 5, 2025, 1:56 PM EDT - 6 months ago

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

MRK RDY

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Jun 4, 2025, 10:29 PM EDT - 6 months ago

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

Jun 4, 2025, 11:32 AM EDT - 6 months ago

Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

Spytime
Spytime Dec. 3 at 2:39 PM
$ALVO Adding more short position today. Technical drop deep. Do it bear.
1 · Reply
Spytime
Spytime Dec. 3 at 12:37 PM
$ALVO another great day is coming. Keep selling all day long.
0 · Reply
Spytime
Spytime Dec. 2 at 9:10 PM
$ALVO Let's go Bear. Keep shorting this daily. Price is not low yet.
1 · Reply
mikesterz7
mikesterz7 Nov. 24 at 12:20 PM
$ALVO 🚨 AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said.
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 24 at 11:56 AM
Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug $ALVO $IBBQ $PRFZ https://stocktwits.com/news/equity/markets/alvotech-drug-approved-in-europe-as-biosimilar-for-bone-disease-drugs/cL5bIelREQc
0 · Reply
nopeZ3
nopeZ3 Nov. 24 at 11:10 AM
$ALVO In at 5.14
0 · Reply
G101SPM
G101SPM Nov. 24 at 11:00 AM
$ALVO $5.14 ask. BUY/NEW LONG POSITION carries SPM 86.45 tag to $12.50 in long term (18 months).
0 · Reply
mru01
mru01 Nov. 24 at 10:57 AM
$ALVO great news!
0 · Reply
islandpunk
islandpunk Nov. 24 at 10:57 AM
$ALVO trending #5. let's go.
0 · Reply
islandpunk
islandpunk Nov. 24 at 10:34 AM
$ALVO Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area https://www.stocktitan.net/news/ALVO/alvotech-announces-approval-of-avt03-a-biosimilar-to-prolia-and-ksdimzmoqfjy.html
0 · Reply
OTCshithead
OTCshithead Nov. 24 at 10:33 AM
$ALVO Alvotech Announces Approval of AVT03, a Biosimilar to Prolia and Xgeva (denosumab) in the European Economic Area
0 · Reply
JarvisFlow
JarvisFlow Nov. 18 at 7:00 PM
UBS has adjusted their stance on Alvotech ( $ALVO ), setting the rating to Buy with a target price of 13 → 10.
0 · Reply
LIKEAG6
LIKEAG6 Nov. 13 at 11:34 AM
$ALVO The cash is running out?
2 · Reply
Donj1956
Donj1956 Nov. 13 at 12:59 AM
$ALVO
0 · Reply
killasimba
killasimba Nov. 12 at 9:19 PM
$ALVO when is the call?
0 · Reply
LIKEAG6
LIKEAG6 Nov. 10 at 3:57 PM
$ALVO Any theories on what the hell is wrong with this stock? I suspect market manipulation but it could also be the Q3 that´s coming up.
1 · Reply
debbiekatz
debbiekatz Nov. 10 at 2:16 PM
$ALVO at 5.95. heading over 7 - posted at 4.98
1 · Reply
abc3000
abc3000 Nov. 10 at 12:20 PM
$ALVO And the hits just keep on comin'!
0 · Reply
FeliciaMath
FeliciaMath Nov. 8 at 5:47 PM
still holding $ALVO too.
0 · Reply
Bigwinner75
Bigwinner75 Nov. 8 at 9:04 AM
$ALVO actually i still dont trust you, i think you work for the shorts, and you just add another short position, we will see
1 · Reply
Bigwinner75
Bigwinner75 Nov. 8 at 8:59 AM
$ALVO
0 · Reply
debbiekatz
debbiekatz Nov. 7 at 9:02 PM
$ALVO 5.68 keep swinging. posted at 4.98
1 · Reply